home / stock / vxrt / vxrt quote
Last: | $0.9934 |
---|---|
Change Percent: | -5.24% |
Open: | $0.905 |
Close: | $0.9934 |
High: | $0.9949 |
Low: | $0.8611 |
Volume: | 2,033,907 |
Last Trade Date Time: | 05/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.9934 | $0.905 | $0.9934 | $0.9949 | $0.8611 | 2,033,907 | 05-22-2024 |
$0.8599 | $0.8823 | $0.8599 | $0.8949 | $0.8431 | 767,163 | 05-21-2024 |
$0.8967 | $0.9588 | $0.8967 | $0.9692 | $0.8605 | 1,593,863 | 05-20-2024 |
$0.9588 | $1.04 | $0.9588 | $1.04 | $0.95 | 1,565,112 | 05-17-2024 |
$1.02 | $0.9999 | $1.02 | $1.06 | $0.94 | 3,201,588 | 05-16-2024 |
$0.9446 | $0.88 | $0.9446 | $0.9499 | $0.8609 | 2,110,742 | 05-15-2024 |
$0.8647 | $0.8987 | $0.8647 | $0.9 | $0.8 | 2,317,345 | 05-14-2024 |
$0.82 | $0.72 | $0.82 | $0.85 | $0.71 | 3,119,476 | 05-13-2024 |
$0.705 | $0.7181 | $0.705 | $0.7429 | $0.69 | 1,985,423 | 05-10-2024 |
$0.7316 | $0.7467 | $0.7316 | $0.7495 | $0.7021 | 930,826 | 05-09-2024 |
$0.73 | $0.73 | $0.73 | $0.7382 | $0.705 | 427,127 | 05-08-2024 |
$0.7384 | $0.77 | $0.7384 | $0.772 | $0.72 | 617,287 | 05-07-2024 |
$0.7662 | $0.74 | $0.7662 | $0.7796 | $0.7301 | 956,214 | 05-06-2024 |
$0.7289 | $0.749 | $0.7289 | $0.7494 | $0.69 | 2,158,370 | 05-03-2024 |
$0.749 | $0.7182 | $0.749 | $0.749 | $0.69 | 1,243,121 | 05-02-2024 |
$0.7006 | $0.7086 | $0.7006 | $0.73 | $0.7 | 714,636 | 05-01-2024 |
$0.7147 | $0.75 | $0.7147 | $0.769 | $0.68 | 1,973,601 | 04-30-2024 |
$0.7133 | $0.7111 | $0.7133 | $0.75 | $0.7 | 1,012,599 | 04-29-2024 |
$0.7097 | $0.6985 | $0.7097 | $0.7097 | $0.6603 | 1,321,643 | 04-26-2024 |
$0.6584 | $0.7 | $0.6584 | $0.724 | $0.6331 | 1,940,133 | 04-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Palo Alto Networks, Inc. (NASDAQ:PANW) reported its third-quarter financial results after the bell Monday. Here's a look at the details from t...
Vaxart, Inc. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. Here's a look at the details. The Details...
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine a...